Abstract
Purpose :
To evaluate the effects of prior patching on visual outcomes and adherence using a digital, binocular treatment for amblyopia) in clinical care setting via a patient registry.
Methods :
Patients with amblyopia were enrolled in a multicentered observational registry if they had ≥12 weeks of Luminopia therapy. Demographic and visual outcome data were extracted. Adherence to the prescribed treatment dose, 1 hour per day 6 days per week, was tracked via software and analyzed for the first 3 months of treatment. We compared outcomes for patients with a history of patching with those who were treatment-naïve; patients with other treatments were excluded from the subgroup analysis.
Results :
Among 62 patients (median age 8 [IQR: 6-10]) included, mean amblyopic eye (AE) BCVA was 0.43±0.26 logMAR at the time of prescription. By the first treatment follow-up, 84±39 days post prescription, mean AE BCVA improved by 0.85 lines to 0.35±0.24 logMAR (p<0.01, 95% CI: -0.12, -0.05); 27 patients (44%) improved by ≥1 lines. Median treatment adherence was 80% (IQR: 56-98%).
For 51 patients (82%) with prior patching, AE BCVA was 0.44±0.25 logMAR at the time of digital prescription and improved by 0.7 lines to 0.36±0.24 logMAR by the first follow-up (p<0.01, 95% CI -0.12, -0.03); 23 patients (51%) improved by ≥1 lines. Median adherence was 79% (IQR: 52-100%).
Conclusions :
Patients had clinically meaningful improvements in vision and strong adherence during the first months of digital amblyopia therapy, consistent with clinical trial results (Xiao 2022). AE BCVA gains and treatment adherence were comparable for those with prior patching and the overall cohort evaluated, with the caveat that currently patients without prior patching make up a small percentage of the registry. As registry enrollment grows, precision of outcome estimates for subgroups will increase and guide individualized treatment recommendations.
This abstract was presented at the 2024 ARVO Annual Meeting, held in Seattle, WA, May 5-9, 2024.